Interim report January - June 2009

GROUP FINANCIAL DEVELOPMENT JANUARY - JUNE • Net sales totaled SEK 43.0 million • Operating income (EBIT) was SEK 13.2 million • Net income after tax was SEK 7.7 million • Results from investing activities totaled SEK 0.0 million • Earnings per share basic/diluted was SEK 0.78 • Equity per share was SEK 37.11 • Equity/assets ratio was 74 percent PARENT COMPANY FINANCIAL DEVELOPMENT JANUARY - JUNE • Results from investing activities was SEK 0.0 million (0.0) • Other revenue amounted to SEK 2.3 million (2.0) • Net loss after tax was SEK -7.2 million (-8.8) KEY EVENTS IN THE SECOND QUARTER • LinkMed carried out a SEK 91.3 million guaranteed preferential rights issue • Olerup International AB acquired Qiagen Vertriebs GmbH and took over the sales and distribution rights of Olerup SSP’s products from Qiagen from July 1, 2009 • AnaMar Medical initiated phase I clinical trials • Olerup SSP’s HLA typing kit is approved by regulatory authorities in Canada • ONCOlog Medical’s advanced treatment table plate AirPlate™ is now in clinical use LINKMED CEO INGEMAR LAGERLÖF COMMENTS ON THE SECOND QUARTER: “Following a successful new issue of shares we have taken meaningful steps in the development of our operations in the transplantation sector. The acquisition of a distribu-tion company from Qiagen and our collaboration with NorDiag are important pieces of the puzzle in further developing the company that we started to build with the acquisi-tion of Olerup SSP. We will now be able to significantly increase profitability for Ab-Sorber’s XM-ONE® as well as Olerup SSP’s products. We are also delighted over very strong sales for Olerup SSP and the new renegotiated agreement with Olle Olerup which enhances our potential of developing this area of our business.”